This biotech just turned in stellar earnings and boosted its guidance for 2015.
SciClone Pharmaceuticals Inc. (SCLN)
from Weiss Stock Ratings Heat Maps
SciClone Pharmaceuticals Inc. (SCLN, Weiss Ratings B+) is a specialty pharmaceutical company that provides therapies for the treatment of oncology, infectious diseases and cardiovascular disorders, primarily in the People’s Republic of China.
It reported better-than-expected earnings and revenue after the bell last night, and its shares responded in great fashion, up more than 17% at midday.
The Foster City, Calif.-based company, getting a big boost from strong demand for its flagship ZADAXIN drug, said fourth-quarter revenue surged 27% from a year earlier, while adjusted earnings per share were 29 cents—up from 3 cents a year ago. ZADAXIN is used to support immune functionality against viruses and cancer.
Even better than the quarterly result, the company guided for EPS to be in the $0.73-$0.77 range for full-year 2015, higher than the $0.64 previously forecast by the two analysts who follow the company.
SciClone Pharmaceuticals Inc. is included in our Best Low-Priced Stocks Heat Map as a buy. And with its latest figures and its breakthrough in treating cancer patients, SCLN warrants serious consideration for any portfolio.
Mike Burnick, Weiss Stock Ratings Heat Maps, published by Money and Markets, a Division of Weiss Research, Inc.,1-800-291-8545, March 12, 2015